文献速递骨质疏松与钙磷/甲状旁腺

绝经后女性延长口服双膦酸盐治疗的健康结局与不良事件:系统综述

Health and adverse events associated with extended oral bisphosphonates among postmenopausal women: a systematic review.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

延长治疗可提高髋部、股骨颈和腰椎骨密度,可能降低临床椎体骨折风险,但增加非典型骨折风险;未报告颌骨坏死。证据异质性大且高质量证据有限,无法得出确定性结论。

要点

  • 延长口服双膦酸盐超过5年可提高髋部、股骨颈和腰椎骨密度。
  • 延长治疗可能降低临床椎体骨折风险,但增加非典型骨折风险。
  • 纳入研究均未评估或报告颌骨坏死。

核心结论

  • 显著异质性和有限的高质量证据使延长口服双膦酸盐治疗无法得出确定性结论。
  • 延长治疗可能改善骨密度并减少椎体骨折,但也可能增加非典型骨折。

研究设计与样本

  • 系统检索Medline、EMBASE和CINAHL自建库至2024年3月15日的文献。
  • 两位作者独立筛选、使用NIH质量评价工具评估质量并提取数据。
  • 遵循PRISMA指南并在PROSPERO注册(CRD42024475332)。
  • 因高度异质性未进行荟萃分析。

主要发现

  • 延长口服双膦酸盐超过5年提高髋部骨密度(3/3项研究)。
  • 提高股骨颈骨密度(3/3项研究)和腰椎骨密度(5/5项研究)。
  • 降低临床椎体骨折风险(1/6项研究)。
  • 增加非典型骨折风险(3/3项研究)和不完全非典型股骨骨折风险(1/1项研究)。
  • 无研究评估或报告颌骨坏死。

关键数值与推荐

  • 国际指南推荐口服双膦酸盐治疗绝经后骨质疏松最长5年。
  • 质量评价:3项研究评为良好,7项为一般,1项为差。

临床怎么用

  • 延长口服双膦酸盐治疗超过5年需权衡骨密度获益与非典型骨折风险。
  • 临床决策应个体化,考虑患者骨折风险与不良事件风险。

局限性

  • 纳入研究高度异质性,无法进行荟萃分析。
  • 高质量证据有限,仅3项研究评为良好质量。
  • 无研究评估或报告颌骨坏死。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: International guidelines recommend the use of oral bisphosphonates (oBP) for up to 5 years in the treatment of postmenopausal osteoporosis. However, benefits and risks of extending oBP therapy beyond this duration remain uncertain. AIM: To determine the health outcomes (bone mineral density [BMD], fracture risk) and adverse effects (atypical fracture, osteonecrosis of the jaw [ONJ]) of extended oBP therapy beyond 5 years among postmenopausal women. METHODOLOGY: A systematic search of Medline©, EMBASE©, and CINAHL© was conducted from inception to 15 March 2024. Interventional and observational studies published in English were included. Two authors independently performed screening, quality appraisal using the NIH Quality Appraisal tool, and data extraction. The review followed PRISMA guidelines and was registered on PROSPERO (CRD42024475332). High heterogeneity precluded meta-analysis. RESULTS: Eleven studies (4 controlled trials, 7 observational) were included: 3 rated as good quality, 7 as fair, and 1 as poor. Extended oBP therapy beyond 5 years increased BMD at the hip (3/3 studies), femoral neck (3/3 studies) and lumbar spine (5/5 studies). Prolonged oBP use reduced clinical vertebral fracture risk (1/6 studies) but increased the risk of atypical fractures (3/3 studies) and incomplete atypical femoral fractures (1/1 study). None of the included studies assessed or reported ONJ. CONCLUSION: Substantial heterogeneity and limited high-quality evidence preclude definitive conclusions regarding extended oBP use in postmenopausal women. While extended treatment may improve bone density and reduce vertebral fractures, it could also increase atypical fractures. Future high-quality studies are required to inform decisions regarding optimal treatment duration.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Oka P, Moosa AS, Koh EYL, et al. Health and adverse events associated with extended oral bisphosphonates among postmenopausal women: a systematic review. J Clin Endocrinol Metab. 2026. PMID: 41668457. doi:10.1210/clinem/dgag057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。